Spineway (ALSPW) Q4 2024 TU earnings summary

Executive summary

• Achieved annual revenue of €11.9 million in FY 2024, representing 14% organic growth year-over-year, driven by successful integration of acquisitions and expansion in premium product ranges.

• Latin America and Asia led growth, with revenue increases of 35% and 12% respectively, while Europe saw modest growth of 2.5% despite market challenges.

• Cost-cutting measures and revenue growth are expected to improve operating performance, particularly EBITDA and operating income.

Financial highlights

• H1 2024 revenue: €6.54 million, up 20% year-over-year; H2 2024 revenue: €5.42 million, up 6% year-over-year.

• Full-year 2024 revenue: €11.95 million, up 14% from €10.52 million in 2023.

• Latin America revenue: €3.1 million (+35% year-over-year); Asia revenue: €1.9 million (+12% year-over-year); Europe revenue: €5.3 million (+2.5% year-over-year).

Outlook and guidance

• Positive business trends support the goal of becoming a major player in less invasive spine treatments.

• Next financial results announcement scheduled for March 24, 2025.